Posted by Michael Wonder on 27 Oct 2021
Novavax files for authorisation of its COVID-19 vaccine in the United Kingdom
27 October 2021 - Filing marks first protein based COVID-19 vaccine submitted to MHRA for authorisation.
Novavax today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency for authorisation of its COVID-19 vaccine candidate.
The company's application for conditional marketing authorisation marks the first submission for authorisation of a protein based COVID-19 vaccine in the United Kingdom.
